Skip to main content
. 2015 Apr 28;5(4):e007435. doi: 10.1136/bmjopen-2014-007435

Table 1.

Patient demographics, chronic asthma factors, acute asthma presentation and emergency department (ED) course for asthma exacerbation, according to the number of ED visits in the 1-year period

1 ED visit 2 ED visits ≥3 ED visits
Variables* (n=784) (n=117) (n=101) p Value
Age (years), median (IQR) 34 (26–43) 34 (25–42) 37 (27–43) 0.45
Male sex 43 (40–47) 41 (32–50) 39 (29–49) 0.64
Current smoker 42 (39–46) 32 (24–42) 49 (38–59) 0.045
Chronic asthma factors
 History of oral corticosteroid use for asthma 35 (31–40) 75 (64–84) 84 (75–91) <0.001
 History of hospital admission for asthma 23 (20–27) 50 (39–61) 66 (55–75) <0.001
 History of intubation for asthma 1 (1–3) 1 (0–7) 8 (3–16) <0.001
 History of hospital admission for asthma in the past year 2 (1–3) 19 (12–28) 34 (25–45) <0.001
 Current use of inhaled corticosteroids 23 (20–26) 45 (36–55) 63 (53–72) <0.001
 Current use of oral xanthines 10 (8–12) 12 (7–20) 26 (18–36) <0.001
 Current use of leukotriene modifiers 8 (6–10) 16 (10–25) 29 (21–39) <0.001
Acute asthma presentation
Duration of symptoms
 <4 h before ED arrival 16 (14–19) 13 (7–20) 21 (13–31) 0.08
 4–23 h 43 (40–47) 49 (39–58) 53 (42–63)
 1–7 days 34 (31–38) 36 (27–46) 22 (14–32)
 >7 days 7 (5–9) 3 (1–8) 4 (1–10)
ED course
 Initial respiratory rate (breath/min), mean (SD) 22±6 21±6 24±6 0.07
 Initial oxygen saturation (%), mean (SD) 95±3 95±4 95±4 0.12
 Initial peak flow† (L/min), mean (SD) 214±103 254±63 170±57 0.21
 Number of inhaled β-agonists in first hour, median (IQR) 1 (1–2) 1 (1–2) 1 (1–2) 0.33
 Number of inhaled β-agonists over ED stay, median (IQR) 1 (1–2) 1 (1–2) 2 (1–2) 0.17
 Received systemic corticosteroid treatment 41 (37–44) 44 (34–53) 62 (52–72) <0.001
ED disposition 0.62
 Sent home 89 (86–91) 86 (79–92) 89 (81–94)
 Hospital admission 11 (9–13) 12 (7–19) 11 (6–19)
 Other (eg, left against medical advice) 1 (0–1) 2 (0–6) 0
Sent home with systemic corticosteroids 35 (32–39) 29 (20–39) 32 (23–43) 0.42

*Data were expressed as % (95% CI) unless otherwise specified.

†Analysed for 56 patients (6%) with initial peak flow available.